|Partial Close, 12/2010 ||$1.69M|
|Series C, 1/2014 |
Capital Midwest Fund
|Debt, 6/2013 ||$4.3M|
ProNAi Therapeutics, Inc. is a DNA Interference (DNAi®)-based biopharmaceutical company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAi®, to advance a next generation of therapies for patients with cancer and other complex genetic diseases.